Blog | BioInformant

Regenerative Outcomes, LLC, Achieves Rapid Growth, as Demand for RMAT Consultancy Expands – Interview with Megan Moneypenny, CEO

May 1, 2019 By Cade Hildreth (CEO) Leave a Comment

I am honored to release this interview with Megan Moneypenny, CEO of Regenerative Outcomes, LLC, a rapidly growing consulting firm within the emerging field of Regenerative Medicine, with a specialty in RMAT consulting. Regenerative Outcomes is an organization that was spun out from the Regenerative Outcomes Foundation, a non-profit group founded by Doug Oliver. Doug has an incredible story of being a stem cell patient, turned renowned advocate and consultant within the field of regenerative medicine. [Read more…]

ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation

April 29, 2019 By Cade Hildreth (CEO) Leave a Comment

MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]

Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant

April 25, 2019 By Cade Hildreth (CEO) Leave a Comment

Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients

BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.

[Read more…]

Dr Professor Eckhard Alt from Germany to Lecture at AAOSCP’s May 2019 Workshop

April 25, 2019 By Cade Hildreth (CEO) Leave a Comment

Dr. Prof. Alt is a Leading Authority on Stem Cells, Electrophysiology, and Interventional Cardiology.

On May 3-5, 2019, the American Academy of Stem Cell Physicians (AAOSCP) will host a Scientific Congress and Workshop, featuring Basic Science to Clinical Practice. The AAOSCP is honored to announce that the event will feature renowned lecturer Eckhard U. Alt, MD, PhD, Professor of Medicine at Technische Universität in Munich, Professor at Tulane University in New Orleans and Professor at University of Texas MD Anderson Cancer Center in Houston. Dr. Prof. Alt is a leading global authority on Stem Cells, Electrophysiology, and Interventional Cardiology, holding more than 650 patents on these subjects worldwide. [Read more…]

Only 30 Days Until the Cell Surgical Conference – CME Regenerative Medical Event

April 24, 2019 By Cade Hildreth (CEO)

With the regenerative medicine market rapidly expanding, there is an increased demand for proficient, qualified medical providers to safely address the growing needs of an aging patient population. While there are numerous opportunities each year to learn these techniques, it is critical to attend events that provide targeted CME education, while expanding your mind, honing your skillset, and placing you among the world’s leaders in regenerative medicine and stem cell applications.

In our opinion, this conference represents one of the leading opportunities for medical providers to learn how regenerative cell therapy is being used across the world and how it can change your practice and your patients’ lives. [Read more…]